Business
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027Operational runway extended to mid-2027, supporting multiple potential value-generating milestonesMatt Angel, Ph.D., joins Tempest as President and CEOPreviously announced transaction closed following stockholder approval of share issuance at the 2025 Annual Meeting on January 27,
About this update from Tempest Therapeutics, Inc.
[{"type":"image","alt":"Tempest Therapeutics","displaySize":"","headline":null,"caption":"Tempest Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":276,"url":"https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1LCUwp9cQJNg7WFUm2vLrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18","width":300,"height":276}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027","length":218,"tagName":"p"}]},{"val":[{"type":"text","content":"Operational runway extended to mid-2027, supporting multiple potential value-generating milestones","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Matt Angel, Ph.D., joins Tempest as President and CEO","length":53,"tagName":"p"}]},{"val":[{"type":"text","content":"Previously announced transaction closed following stockholder approval of share issuance at the 2025 Annual Meeting on January 27, 2026","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":504,"olType":false},{"type":"text","content":"BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeutic assets, today announced the closing of a previously announced transaction pursuant to which Tempest acquired certain dual-targeting chimeric antigen receptor (CAR)-T programs and obtained financing support from Factor Bioscience Inc. and its affiliates (collectively, “Factor”) in an all-stock transaction resulting in a diverse portfolio including clinical-stage product candidates and an extended runway with multiple potential near-term milestones (the “Transaction”).","length":667,"tagName":"p"},{"type":"text","content":"“I am excited to join the Tempest team and to have the opportunity to develop this innovative pipeline of potential therapies to treat a range of solid tumors and hematologic malignancies,” said Dr. Matt Angel, President and Chief Executive Officer of Tempest....